7:00 am Breakfast Briefing Hosted by Bio-Rad – Attendance by Invitation Only

7:55 am Chair’s Opening Remarks

8:00 am Late Breaking Abstracts

Synopsis

Tumor Tissue Mechanisms that Facilitate or Restrict the Activity of Genetically Engineered T Cells

Adrian Bot, VP, Translational Medicine, Kite, a Gilead Company

8:30 am Terumo BCT

9:00 am GE Healthcare

9:30 am Eversana

10:00 am Morning Refreshments & Networking

10:30 am Tech slam

1:00 pm Lunchtime Refreshments & Networking

3:30 pm Afternoon Refreshments & Networking

4:00 pm FDA’s Efforts to Facilitate the Development of the Next Generation of CAR-T Cells

4:30 pm Debate Session: CAR-TCR Vs Bispecifics

  • Peter Emtage Global Head of Cell Therapy Research, Kite, a Gilead Company
  • Faraz Zaman Acute Leukemia Global Medical Lead, Amgen

5:00 pm Putting Patients First: How Has the Face of Cancer Therapy Changed

5:20 pm Closing Remarks

5:25 pm Close of of 6th Annual CAR-TCR Summit 2020